Camurus AB (publ) (STO:CAMX)

Sweden flag Sweden · Delayed Price · Currency is SEK
603.00
-6.50 (-1.07%)
Jun 16, 2025, 5:29 PM CET
10.54%
Market Cap 35.50B
Revenue (ttm) 2.04B
Net Income (ttm) 547.78M
Shares Out 58.88M
EPS (ttm) 9.17
PE Ratio 65.75
Forward PE 35.20
Dividend n/a
Ex-Dividend Date n/a
Volume 102,043
Average Volume 347,731
Open 605.00
Previous Close 609.50
Day's Range 595.00 - 606.50
52-Week Range 483.80 - 715.00
Beta 0.48
RSI 53.61
Earnings Date Jul 17, 2025

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1991
Employees 256
Stock Exchange Nasdaq Stockholm
Ticker Symbol CAMX
Full Company Profile

Financial Performance

In 2024, Camurus AB's revenue was 1.87 billion, an increase of 8.78% compared to the previous year's 1.72 billion. Earnings were 428.39 million, a decrease of -0.71%.

Financial Statements

News

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in pote...

13 days ago - PRNewsWire

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

LUND, Sweden , April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positi...

7 weeks ago - PRNewsWire

Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ...

Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid Regulatory Challenges

7 months ago - GuruFocus

Q3 2024 Camurus AB Earnings Call Transcript

Q3 2024 Camurus AB Earnings Call Transcript

7 months ago - GuruFocus

US FDA declines to approve Camurus' rare hormone disorder drug

The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugm...

8 months ago - Reuters

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3...

1 year ago - PRNewsWire